早期68 Ga-FAP-2286 PET成像的可行性：一项病例研究。

Feasibility of Early 68 Ga-FAP-2286 PET Imaging: A Case Study.

作者信息

Banihashemian Seyedeh Somayyeh, Divband Ghasemali, Shahrnoy Abdolghafar Abolhosseini, Nami Reza, Nasiri Meysam, Akbari Mohammad Esmaeil

机构信息

From the Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Khatam PET-CT Center, Khatam-al-Anbia Hospital, Tehran, Iran.

出版信息

Clin Nucl Med. 2025 Feb 1;50(2):e94-e95. doi: 10.1097/RLU.0000000000005519. Epub 2024 Nov 6.

DOI:10.1097/RLU.0000000000005519

PMID:39501486

Abstract

Fibroblast activation protein (FAP) has emerged as a promising molecular target for diagnostic and therapeutic strategies. Previous research, including our own study and other published reports, has highlighted the potential of FAP inhibitors labeled with 68 Ga as effective diagnostic radiopharmaceuticals. In this study, we present a comparative analysis of early and late PET/CT scans, using 68 Ga-FAP-2286, for the detection of tumor lesions in a patient with metastatic breast adenocarcinoma.

摘要

成纤维细胞活化蛋白（FAP）已成为诊断和治疗策略中一个有前景的分子靶点。先前的研究，包括我们自己的研究以及其他已发表的报告，都强调了用68Ga标记的FAP抑制剂作为有效诊断性放射性药物的潜力。在本研究中，我们对一名转移性乳腺腺癌患者使用68Ga-FAP-2286进行早期和晚期PET/CT扫描检测肿瘤病变进行了对比分析。